Royal Bank Of Canada Initiates Coverage on Medpace (NASDAQ:MEDP)

Analysts at Royal Bank Of Canada initiated coverage on shares of Medpace (NASDAQ:MEDP) in a report released on Tuesday, MarketBeat.com reports. The brokerage set an “outperform” rating and a $522.00 price target on the stock. Royal Bank Of Canada’s price target would suggest a potential upside of 12.05% from the company’s previous close.

Several other research firms have also weighed in on MEDP. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and lowered their target price for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Truist Financial dropped their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. Barclays decreased their target price on Medpace from $525.00 to $500.00 and set an “underweight” rating for the company in a research note on Wednesday, February 11th. Finally, Zacks Research cut Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Five equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $486.67.

Medpace Stock Up 0.1%

Shares of Medpace stock opened at $465.86 on Tuesday. The business has a 50-day moving average price of $537.93 and a 200 day moving average price of $538.85. Medpace has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The firm has a market cap of $13.22 billion, a P/E ratio of 30.45, a P/E/G ratio of 2.23 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business’s revenue was up 32.0% on a year-over-year basis. During the same quarter last year, the firm earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts anticipate that Medpace will post 12.29 earnings per share for the current year.

Institutional Trading of Medpace

Large investors have recently added to or reduced their stakes in the business. Clarkston Capital Partners LLC acquired a new position in shares of Medpace during the second quarter valued at approximately $40,569,000. Cibc World Market Inc. bought a new position in Medpace during the 3rd quarter valued at $5,033,000. Brighton Jones LLC increased its position in shares of Medpace by 160.4% during the 3rd quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock valued at $2,087,000 after purchasing an additional 2,501 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in shares of Medpace by 150.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock worth $8,080,000 after buying an additional 9,117 shares in the last quarter. Finally, Baillie Gifford & Co. lifted its holdings in shares of Medpace by 12.0% in the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after buying an additional 62,503 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.